Generation and Characterization of Amyotrophic Lateral Sclerosis iPS cells
Generation and Characterization of Amyotrophic Lateral Sclerosis iPS cells
批准号:
7855283
负责人:
MERIT E CUDKOWICZ
金额:
$186.26万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-09-30 至 2011-08-31
关键词:
AdultAgeAmyotrophic Lateral SclerosisAstrocytesBiologyBiopsyCell CommunicationCell LineCell modelCellsCellular biologyCharacteristicsCollaborationsDevelopmentDiseaseFibroblastsFunctional disorderGenerationsGeneticGlutamatesHumanHuman Cell LineLeadMembrane PotentialsMethodsMotor NeuronsMutationNerve DegenerationNeurodegenerative DisordersPathway AnalysisPathway interactionsPatientsPrincipal InvestigatorPropertyProteinsProtocols documentationSeriesSiteSkinSpecificitySpinalTranslational ResearchWorkcell typedrug discoverygenetic analysishuman embryonic stem cellhuman embryonic stem cell lineinsightmeetingsmutantnovel therapeuticspublic health relevancerelating to nervous systemstemnesstool
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Although we do not fully know if disease study of cells in Petri dishes can fully emulate the developmental progression that occurs in human adult neurodegenerative disease like ALS, new described technical ability to generate Induced Pluripotent Cells (iPS) from ALS patients provides an exceptional tool by which we can explore these issues. Many recent insights into the pathophysiology of ALS come from the study of familial forms of this disease. The ability to actually have human cell lines- representing the natural disease in the most relevant cell types- motor neurons and astrocytes- will provide unprecedented tools to 1) study cell- cell interactions responsible for disease pathophysiology and 2) provide critical tools for drug discovery and genetic pathway analysis. Eventually these ALS cell lines will also be useful to compare common and uncommon pathways between ALS and other neurodegenerative iPS models. But - iPS cell biology is exceptionally new and we do not yet have sufficient information about the reliability of the cells generated, their ability to truly reflect human cell biology, recapitulate the protein, genetic and functional characteristics of native motor neurons and astroglia. Before we can embark on extensive use of these cells for basic/translational research- it would be critical to generate a series of cell lines- all produced under identical conditions, from different fALS mutations, to determine how representative they are for cell type specificity and functional biology. The overall proposal will involve four principal investigators, working in tight collaboration, to generate and evaluate familial ALS (fALS) iPS cell lines. Project 1, led by Dr. Eggan will obtain the skin biopsies from FALS and control patients, generate the fibroblast and ultimately the initial iPS lines. We will employ the aid of iZumi, a biotech company to be a central site for uniform protocol iPS cell generation. iPS cell lines with neural/glial characteristics will be sent to the Project 2 Lab- Motor neuron biology, lead by Chris Henderson and to Project 3 lab, Astrocytes- lead by Jeffrey Rothstein. These two projects/labs will determine which of the fALS iPS cell lines have the appropriate characteristics of motor neurons and astroglia, through a series of sequential analyses. Only those cell lines that meet final criteria (as compared to human ES cell and prior work on human astroglia) will then go on for final genetic analysis in the Project 4 lab, lead by Tom Maniatis.
PUBLIC HEALTH RELEVANCE: Understanding the pathophysiology and development of new therapeutics for ALS has been an enormous challenge. The ability to actually have human cell lines- representing the natural disease in the most relevant cell types- motor neurons and astrocytes- will provide unprecedented tools to 1) study cell- cell interactions responsible for disease pathophysiology and 2) provide critical tools for drug discovery and genetic pathway analysis. Eventually these ALS cell lines will also be useful to compare common and uncommon pathways between ALS and other neurodegenerative iPS models. )
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Clinical Coordinating Center for the Network of Excellence in Neuroscience Clinical Trials (NEXT - CCC)
-
批准号:10741962
-
项目类别:
-
资助金额:$283.53万
-
财政年份:2023
-
负责人:MERIT E CUDKOWICZ
-
依托单位:
Clinical Coordinating Center Network of Excellence in Neuroscience Clinical Trial
-
批准号:10468050
-
项目类别:
-
资助金额:$239.4万
-
财政年份:2011
-
负责人:MERIT E CUDKOWICZ
-
依托单位:
Clinical Coordinating Center Network of Excellence in Neuroscience Clinical Trial
-
批准号:10213840
-
项目类别:
-
资助金额:$240.23万
-
财政年份:2011
-
负责人:MERIT E CUDKOWICZ
-
依托单位:
Clinical Coordinating Center Network of Excellence in Neuroscience Clinical Trial
-
批准号:8539105
-
项目类别:
-
资助金额:$274.22万
-
财政年份:2011
-
负责人:MERIT E CUDKOWICZ
-
依托单位:
Clinical Coordinating Center Network of Excellence in Neuroscience Clinical Trial
-
批准号:8338822
-
项目类别:
-
资助金额:$267.27万
-
财政年份:2011
-
负责人:MERIT E CUDKOWICZ
-
依托单位:
Clinical Coordinating Center Network of Excellence in Neuroscience Clinical Trial
-
批准号:8885926
-
项目类别:
-
资助金额:$260.14万
-
财政年份:2011
-
负责人:MERIT E CUDKOWICZ
-
依托单位:
Clinical Coordinating Center Network of Excellence in Neuroscience Clinical Trial
-
批准号:9069323
-
项目类别:
-
资助金额:$10.26万
-
财政年份:2011
-
负责人:MERIT E CUDKOWICZ
-
依托单位:
Clinical Coordinating Center Network of Excellence in Neuroscience Clinical Trial
-
批准号:10015348
-
项目类别:
-
资助金额:$239.52万
-
财政年份:2011
-
负责人:MERIT E CUDKOWICZ
-
依托单位:
Clinical Coordinating Center Network of Excellence in Neuroscience Clinical Trial
-
批准号:8550171
-
项目类别:
-
资助金额:$8.25万
-
财政年份:2011
-
负责人:MERIT E CUDKOWICZ
-
依托单位:
Clinical Coordinating Center Network of Excellence in Neuroscience Clinical Trial
-
批准号:9308007
-
项目类别:
-
资助金额:$232.21万
-
财政年份:2011
-
负责人:MERIT E CUDKOWICZ
-
依托单位:
Clinical Coordinating Center Network of Excellence in Neuroscience Clinical Trial
-
批准号:8239805
-
项目类别:
-
资助金额:$274.1万
-
财政年份:2011
-
负责人:MERIT E CUDKOWICZ
-
依托单位:
Generation and Characterization of Amyotrophic Lateral Sclerosis iPS cells
-
批准号:8145784
-
项目类别:
-
资助金额:$8.2万
-
财政年份:2009
-
负责人:MERIT E CUDKOWICZ
-
依托单位:
Generation and Characterization of Amyotrophic Lateral Sclerosis iPS cells
-
批准号:7941744
-
项目类别:
-
资助金额:$183.74万
-
财政年份:2009
-
负责人:MERIT E CUDKOWICZ
-
依托单位:
CLINICAL TRIAL: OPEN-LABEL ARIMOCLOMOL EXTENSION PROTOCOL
-
批准号:7731270
-
项目类别:
-
资助金额:$0.02万
-
财政年份:2008
-
负责人:MERIT E CUDKOWICZ
-
依托单位:
SAFETY AND PHARMACOKINETICS STUDY OF ARIMOCLOMOL IN ALS
-
批准号:7607069
-
项目类别:
-
资助金额:$1.96万
-
财政年份:2006
-
负责人:MERIT E CUDKOWICZ
-
依托单位:
IDENTIFICATION OF DIAGNOSTIC BIOMARKERS AND THERAPEUTIC AGENTS FOR ALS
-
批准号:7607080
-
项目类别:
-
资助金额:$0.71万
-
财政年份:2006
-
负责人:MERIT E CUDKOWICZ
-
依托单位:
OPEN-LABEL ARIMOCLOMOL EXTENSION PROTOCOL
-
批准号:7607085
-
项目类别:
-
资助金额:$1.22万
-
财政年份:2006
-
负责人:MERIT E CUDKOWICZ
-
依托单位:
MULTI-DOSE PLACEBO-CONTROLLED PHASE I STUDY OF AEOL 10150 IN PATIENTS WITH ALS
-
批准号:7607079
-
项目类别:
-
资助金额:$1.29万
-
财政年份:2006
-
负责人:MERIT E CUDKOWICZ
-
依托单位:
Coenzyme Q10 in Huntington's Disease
-
批准号:6964108
-
项目类别:
-
资助金额:$117.51万
-
财政年份:2005
-
负责人:MERIT E CUDKOWICZ
-
依托单位:
DOUBLE BLIND STUDY OF MINOCYCLINE IN HD
-
批准号:7474777
-
项目类别:
-
资助金额:$41.18万
-
财政年份:2005
-
负责人:MERIT E CUDKOWICZ
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: